PolyPeptide Group is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group.
PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing.
PolyPeptide’s shares (PPGN) are listed on the Swiss Stock Exchange SIX.